Evaluating the Impact of Ocimumgratissimum and Verononia amygdalina on Glycated Hemoglobin in Niacin - Induced Type 2- Diabetes

The cost of conventional anti-diabetic drugs, their accessibility coupled with increased non- compliance among patients necessitates the need for a more acceptable, accessible and cheap alternative to lowering Glycated Hemoglobin (GHb) in type 2- diabetes. To evaluate the impact of Ocimumgratissimum (OG) and Verononia amygdalina (VA) on GHb in type 2- diabetes, type II diabetes was induced using 100 mg/kg niacin, l hour before the administration of 65 mg/kg STZ. Once diabetes once established by testing with a glucometer, OG and VA were administered and compared with negative and positive controls. GHb concentrations for the various groups were measured using Ion-Exchange Resin Method and the results analysed using One Way ANOVA.VA showed a significant (pless than0.001) reduction in glycated hemoglobin as well as a significant (pless than0.05) reduction in GHb was observed in the group treated with OG+ VA. Thus, daily treatment with OG and VA drastically reduces glycated hemoglobin levels in type 2 diabetes under niacin coverage; improving clinical outcomes of type 2 diabetic rats.